Ofev (nintedanib) helped more patients with progressive fibrosing interstitial lung diseases (ILDs) avoid a decline in lung function greater than 10% over the course of a year compared with those given a placebo, according to a new analysis of the Phase 3 INBUILD trial. A separate analysis…
News
Note: This story was updated Aug. 11, 2020, to correct the name of the factor involved in fibrosis to TGF-alpha rather than TNF-alpha. Barasertib, AstraZeneca’s investigational inhibitor of the AURKB protein, eased the activation of fibroblasts and lessened lung scarring in two mouse models of idiopathic pulmonary…
AstraZeneca has acquired a global license for RXC006, an investigational porcupine inhibitor for treating fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), providing $17 million in initial funding to the therapy’s developer Redx Pharma. AstraZeneca plans to advance RXC006 to a Phase 1 clinical study. The agreement includes a…
To help people experiencing the lingering effects of coronavirus infection, the Pulmonary Wellness Foundation (PWF) has launched a free online rehabilitation and recovery program called COVID Bootcamp 101. In addition to patient education and support, the program offers breathing and other exercises conducted by a team of…
The European Research Council (ERC) has awarded the Institute for Research in Biomedicine (IRB) Barcelona a €150,000 ($176,000) Proof of Concept grant to develop new medications to treat fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). The grant, which provides for 18 months of funding, also…
People with idiopathic pulmonary fibrosis (IPF) are at increased risk of several cancers other than lung cancer, a new study reports. The study, “Risk of cancer incidence in patients with idiopathic pulmonary fibrosis: A nationwide cohort study,” was published in the journal Respirology. IPF and…
Blocking an enzyme — called 15-PGDH — in a mouse model of pulmonary fibrosis (PF) limited early-stage inflammation and the development of fibrosis in the lungs, aiding the animals’ survival, a study demonstrated. These findings support further work targeting 15-PGDH as a…
Conditions affecting the heart, stomach, and esophagus occur more frequently in patients whose diagnosis of idiopathic pulmonary fibrosis (IPF) is delayed, coming more than one year after the onset of symptoms, according to a recent study. This delayed diagnosis seems, however, to have no impact on the risk of…
A three-year pulmonary rehabilitation program — a combination of aerobic, resistance, and breathing exercises — helped to maintain lung and muscle strength before a double-lung transplant in a middle-aged man with idiopathic pulmonary fibrosis (IPF) and a sedentary lifestyle, a case study reports. The study “Long-Term…
Biognosys and Boehringer Ingelheim are working together to expand the use of cutting-edge technologies for large-scale protein analysis in drug discovery, beginning with a study of potential new treatment approaches to idiopathic pulmonary fibrosis (IPF). Biognosys announced that it will bring its expertise in proteomics — the…
